Since current trials have reported limited efficacy of PD-1/PD-L1 blocker in MDS/AML, numerous ongoing efforts are being made for assessing the effectiveness of novel combinations, including with novel HMAs, other immune checkpoint inhibitors (ICIs), histone deacetylase inhibitors (HDACi), tumor vaccines or chemotherapeutic agents (Table 3). The gene discussed is PDCD1; the disease is myelodysplastic syndrome.